Capmatinib successfully overcomes tepotinib ‐induced intolerable peripheral edema

Peripheral edema has been identified as one of the most common adverse events in capmatinib and tepotinib; however, there is no unified management for this side effect. This is the first report that two MET inhibitors have different effects on the development of peripheral edema, and that the MET inhibitors can be continued by switching these drugs. AbstractIn May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non-small cell lung carcinoma harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Herein, we present a case of intolerable peripheral edema caused by tepotinib, in which MET inhibitor could be continued by switching to capmatinib. Peripheral edema has been identified as one of the most common adverse events in capmatinib and tepotinib; however, there is no unified management for this adverse event. This is the first report that two MET inhibitors have different effects on the development of peripheral edema, and that the MET inhibitors can be continued by switching these drugs.

Source: Thoracic Cancer - October 25, 2021 Category: Cancer & Oncology Authors: Kei Kunimasa, Takahisa Kawamura, Motohiro Tamiya, Takako Inoue, Hanako Kuhara, Kazumi Nishino, Toru Kumagai Tags: CASE REPORT Source Type: research